NMTR - 9 Meters Biopharma, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Raleigh,
United States
NMTR price evolution
NMTR
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $37.24 | $46.99 | $53.61 | $64.02 |
| Short term investments | $0.07 | |||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $39.09 | $49.99 | $56.48 | $65.78 |
| Long term investments | ||||
| Property, plant & equipment | $0.17 | $0.18 | $0.2 | $0.21 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.18 | $0.19 | $0.2 | $0.21 |
| Total investments | $0.07 | |||
| Total assets | $39.26 | $50.17 | $56.68 | $65.99 |
| Current liabilities | ||||
| Accounts payable | $1.91 | $2.43 | $1.32 | $1.64 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $8.22 | $8.46 | $7.28 | $6.72 |
| Long term debt | $0.1 | $0.11 | $0.13 | $0.14 |
| Total noncurrent liabilities | $0.1 | $0.11 | $0.13 | $0.14 |
| Total debt | $0.1 | $0.11 | $0.13 | $0.14 |
| Total liabilities | $8.32 | $8.57 | $7.41 | $6.86 |
| Shareholders' equity | ||||
| Retained earnings | -$180.19 | -$168.84 | -$159.29 | -$145.75 |
| Other shareholder equity | $0 | |||
| Total shareholder equity | $30.94 | $41.6 | $49.27 | $59.14 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $46.99 | $37.85 | $4.59 | $5.73 |
| Short term investments | $0.07 | $0.07 | $0.07 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $49.99 | $38.93 | $5.22 | $6.41 |
| Long term investments | ||||
| Property, plant & equipment | $0.18 | $0.23 | $0.07 | $0.04 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.19 | $0.23 | $0.07 | $0.04 |
| Total investments | $0.07 | $0.07 | $0.07 | |
| Total assets | $50.17 | $39.16 | $5.3 | $6.45 |
| Current liabilities | ||||
| Accounts payable | $2.43 | $1.49 | $3.89 | $3.62 |
| Deferred revenue | ||||
| Short long term debt | $0.01 | $3.18 | $5.2 | |
| Total current liabilities | $8.46 | $6.85 | $14.91 | $10.11 |
| Long term debt | $0.11 | $0.17 | ||
| Total noncurrent liabilities | $0.11 | $0.17 | ||
| Total debt | $0.11 | $0.18 | $3.18 | $5.2 |
| Total liabilities | $8.57 | $7.02 | $14.91 | $10.11 |
| Shareholders' equity | ||||
| Retained earnings | -$168.84 | -$132.06 | -$70.56 | -$43.52 |
| Other shareholder equity | $0 | |||
| Total shareholder equity | $41.6 | $32.14 | -$9.61 | -$3.66 |
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $8.37 | $7.05 | $6.05 | $5.71 |
| Selling, general & administrative | $3 | $2.52 | $2.39 | $2.55 |
| Total operating expenses | $11.36 | $9.56 | $13.54 | $8.26 |
| Operating income | -$11.36 | -$9.56 | -$13.54 | -$8.26 |
| Income from continuing operations | ||||
| EBIT | -$11.35 | -$9.55 | -$13.54 | -$8.25 |
| Income tax expense | ||||
| Interest expense | $0 | $0 | $0 | |
| Net income | ||||
| Net income | -$11.35 | -$9.55 | -$13.54 | -$8.25 |
| Income (for common shares) | -$11.35 | -$9.55 | -$13.54 | -$8.25 |
| (in millions $) | 30 Jan 2022 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $10.93 | $13.72 | $7.56 | |
| Selling, general & administrative | $10.52 | $10.57 | $10.66 | |
| Total operating expenses | $53.72 | $24.28 | $18.22 | |
| Operating income | -$53.72 | -$24.28 | -$18.22 | |
| Income from continuing operations | ||||
| EBIT | -$57.45 | -$25.22 | -$18.01 | |
| Income tax expense | ||||
| Interest expense | $4.05 | $1.83 | $6.15 | |
| Net income | ||||
| Net income | -$61.5 | -$27.05 | -$24.16 | |
| Income (for common shares) | -$61.5 | -$27.05 | -$24.16 | |
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Net income | -$11.35 | -$9.55 | -$13.54 | -$8.25 |
| Operating activities | ||||
| Depreciation | $0 | $0 | $0 | $0 |
| Business acquisitions & disposals | -$2.49 | |||
| Stock-based compensation | $0.69 | $0.53 | $0.53 | $0.94 |
| Total cash flows from operations | -$9.75 | -$7.97 | -$8.17 | -$7.11 |
| Investing activities | ||||
| Capital expenditures | -$0 | -$0 | -$0 | -$0 |
| Investments | $0.07 | |||
| Total cash flows from investing | -$0 | -$0 | -$2.42 | -$0 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.36 | $0.43 | $35.29 | |
| Net borrowings | ||||
| Total cash flows from financing | $1.36 | $0.18 | $32.64 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$9.75 | -$6.62 | -$10.41 | $25.53 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$36.78 | -$61.5 | -$27.05 | -$24.16 |
| Operating activities | ||||
| Depreciation | $0.01 | $0.02 | $0.02 | $0.02 |
| Business acquisitions & disposals | -$2.49 | -$3.18 | ||
| Stock-based compensation | $2.41 | $4.72 | $2.87 | $3.81 |
| Total cash flows from operations | -$29.48 | -$19.41 | -$17.97 | -$15.17 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0 | -$0.01 | -$0.01 |
| Investments | $0.07 | |||
| Total cash flows from investing | -$2.43 | -$3.19 | -$0.01 | -$0.01 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $44.01 | $39.68 | $20.74 | $17.75 |
| Net borrowings | -$0.06 | $0.02 | -$2.85 | $3.02 |
| Total cash flows from financing | $41.05 | $55.86 | $16.84 | $20.56 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $9.14 | $33.26 | -$1.14 | $5.37 |
News
Fundamentals
| Market cap | $58.10M |
|---|---|
| Enterprise value | $20.96M |
| Shares outstanding | 258.24M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$42.69M |
| EBIT | -$42.70M |
| Net Income | -$42.70M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -1.36 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -0.49 |
| EV/EBIT | -0.49 |
| P/S ratio | N/A |
| P/B ratio | 1.88 |
| Book/Share | 0.12 |
| Cash/Share | 0.14 |
| EPS | -$0.17 |
|---|---|
| ROA | -80.52% |
| ROE | -94.39% |
| Debt/Equity | 0.21 |
|---|---|
| Net debt/EBITDA | 0.68 |
| Current ratio | 4.75 |
| Quick ratio | 4.75 |